Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 24, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 11, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Aug 6, 2026Reported sale · Form 4Mark C. Schneyer, EVP, CHIEF FINANCIAL OFFICER · $145.0KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record1,2318 flagged findings
Reported transactions (Form 4)80since Mar 6, 2026
Corporate events (8-K)30since Jun 8, 2018
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-07listing compliance noticerecentOpen filing ↗“…we may acquire or in-license; • disputes or other developments concerning our proprietary and intellectual property rights; 60 •…”
+1 more passage from the same document
- “…us, including any new products that we may acquire or in-license; • disputes or other developments concerning our proprietary and…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 1,231)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 24, 268-K ↗Current report · Communication to the market · Other events
- Sep 11, 268-K ↗Current report · Other events
- Aug 7, 26Form 4 ↗Insider transaction
- Aug 7, 26SCHEDULE 13G ↗Passive stake · STATE STREET CORPORATION · 5.3% · event on Jun 30, 26
- Aug 5, 26Form 144 ↗Notice of proposed sale
- Aug 5, 2610-Q ↗Quarterly report
- Aug 4, 268-K ↗Current report · Results
- Jun 26, 26Form 144 ↗Notice of proposed sale
Insider transaction · 7 Form 4 filingsshow all 7hide
- May 29, 268-K ↗Current report · A senior executive left or was appointed
- May 27, 26Form 4 ↗Insider transaction
- May 26, 26Form 144 ↗Notice of proposed sale
- May 7, 2610-Q ↗Quarterly report
- May 6, 268-K ↗Current report · Results
- May 1, 268-K ↗Current report · A senior executive left or was appointed
1,231 filings on record, the oldest from May 26, 04.
Listing the 25 most recent filings of the 1,231 on record.
44660
4 senior executive changes2025 – 2026show all 4hide
- May 29, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- May 1, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Mar 5, 26A senior executive left or was appointed8-K 5.02 ↗
- Nov 3, 25A senior executive left or was appointed8-K 5.02 ↗
- May 20, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Dec 11, 24Completed an acquisition or disposal8-K 2.01 ↗
4 senior executive changes2024show all 4hide
- Nov 20, 24A senior executive left or was appointed8-K 5.02 ↗
- Sep 23, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 29, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jan 31, 24A senior executive left or was appointed8-K 5.02 ↗
- Jul 18, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
9 senior executive changes2020 – 2022show all 9hide
- Oct 28, 22A senior executive left or was appointed8-K 5.02 ↗
- Oct 13, 22A senior executive left or was appointed8-K 5.02 ↗
- Jun 10, 22A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 8, 22A senior executive left or was appointed8-K 5.02 ↗
- Dec 14, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Nov 5, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Sep 2, 21A senior executive left or was appointed8-K 5.02 ↗
- Jan 27, 21A senior executive left or was appointed8-K 5.02 ↗
- Oct 1, 20A senior executive left or was appointed8-K 5.02 ↗
- Aug 25, 20Sold unregistered shares+2 more in the same filing8-K 3.02 ↗
9 senior executive changes2018 – 2020show all 9hide
- Aug 6, 20A senior executive left or was appointed8-K 5.02 ↗
- Jun 29, 20A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Nov 7, 19A senior executive left or was appointed8-K 5.02 ↗
- Jun 28, 19A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Apr 1, 19A senior executive left or was appointed8-K 5.02 ↗
- Nov 20, 18A senior executive left or was appointed8-K 5.02 ↗
- Nov 5, 18A senior executive left or was appointed8-K 5.02 ↗
- Jul 23, 18A senior executive left or was appointed8-K 5.02 ↗
- Jun 8, 18A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
The record reaches back to Jan 14, 05.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Nov 9, 10Listing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
- Aug 5, 10Listing notice (8-K 3.01)8-K 3.01 ↗
- Oct 15, 09Restructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗
- Jul 28, 09Listing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
The full record holds 4 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Julian C. Baker25.4%Feb 24, 26SCHEDULE 13D/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.11.9%Jan 31, 25SCHEDULE 13G/A ↗
- STATE STREET CORPORATION5.3%Jun 30, 26SCHEDULE 13G ↗
- Vanguard Portfolio Management5.2%Mar 31, 26SCHEDULE 13G ↗
- RTW Investments, LP4.2%Sep 30, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Aug 5, Schneyer Mark C. filed notice of intent to sell up to $159K. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $587K across 3 trades, between Aug 5 and Aug 6, per their Form 4. Their sales over those 90 days far exceed the amount announced here.
View notice (Form 144) ↗+1 more recent notices · 1 with a later sale
- Aug 6, 26Sell$145KMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER↗
- Aug 6, 26Sell$273KMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER↗
- Aug 5, 26Sell$170KMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER↗
- Jul 30, 26Sell$431KElizabeth H.Z. ThompsonEVP, Head of Research & Dev↗
- Jul 30, 26Sell$1KElizabeth H.Z. ThompsonEVP, Head of Research & Dev↗
- Jun 26, 26Sell$298KJames KiharaPRINCIPAL ACCOUNTING OFFICER↗
- May 26, 26Sell$114KJames KiharaPRINCIPAL ACCOUNTING OFFICER↗
- May 4, 26Sell$29KJames KiharaPRINCIPAL ACCOUNTING OFFICER↗
- May 4, 26Sell$76KMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER↗
- Apr 7, 26Sell$23KJames KiharaPRINCIPAL ACCOUNTING OFFICER↗
- Apr 7, 26Sell$60KMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER↗
- Mar 26, 26Sell$24KJames KiharaPRINCIPAL ACCOUNTING OFFICER↗
There are 8 more transactions in this stretch.
Stock compensation, tax and giftsshow the 20 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Aug 6, 26Compensation$255KMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER↗
- Aug 5, 26Compensation$104KMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER↗
- Jul 29, 26Compensationamount n/aElizabeth H.Z. ThompsonEVP, Head of Research & Dev↗
- May 29, 26Compensationamount n/aEDMUND HARRIGAN↗
- May 29, 26Compensationamount n/aLaura Brege↗
- May 29, 26Compensationamount n/aJames M Daly↗
- May 29, 26Compensationamount n/aJonathan Poole↗
- May 29, 26Compensationamount n/aELIZABETH A. GAROFALO↗
- May 29, 26Compensationamount n/aAdora Ndu↗
- May 29, 26Compensationamount n/aBAKER BROS. ADVISORS LP↗
- May 1, 26Compensationamount n/aJames KiharaPRINCIPAL ACCOUNTING OFFICER↗
- May 1, 26Compensationamount n/aMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER↗
- Apr 5, 26Compensationamount n/aJames KiharaPRINCIPAL ACCOUNTING OFFICER↗
- Apr 5, 26Compensationamount n/aMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER↗
- Mar 25, 26Compensationamount n/aJames KiharaPRINCIPAL ACCOUNTING OFFICER↗
- Mar 25, 26Compensationamount n/aMark C. SchneyerEVP, CHIEF FINANCIAL OFFICER↗
- Mar 24, 26Compensationamount n/aJennifer J RhodesEVP, CHIEF LEGAL OFFICER, SEC↗
- Mar 24, 26Compensationamount n/aJames KiharaPRINCIPAL ACCOUNTING OFFICER↗
- Mar 24, 26Compensationamount n/aAdams Catherine OwenChief Executive Officer↗
- Mar 24, 26Compensationamount n/aElizabeth H.Z. ThompsonEVP, Head of Research & Dev↗
The full record holds 258 transactions and goes back to Jun 22, 21.
Its sector and its market
Acadia Pharmaceuticals Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Acadia Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Acadia Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 1,231 documents on file, from May 26, 2004 to Sep 24, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 18, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.